Abstract
Macular edema is a frequent long-term complication of chronic uveitis, confirmed by a number of epidemiological studies. Its prevalence among uveitis patients is estimated between 20 and 30 % and is a major cause of permanent vision loss [1–3]. About 35 % of uveitis patients with a vision less than 0.1 (6/60) have macular edema, though its prevalence as a cause of poor vision varies with the duration of uveitis. It is reported in 17 % of cases at year 1 and increases to 30 % by year 5 [4].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Rothova A, Suttorp- van Schulten MSA, Terffers WF, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80:332–6.
Lardenoye CWTA, van Kooij B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology. 2006;113(8):1446–9.
Rothova A. Inflammatory cystoid macular edema. Curr Opin Ophthalmol. 2007;18:487–92.
Smith JA, Mackensen F, Sen HN, Leigh JF, Watkins AS, Pyatetsky D, et al. Epidemiology and course of disease in childhood uveitis. Ophthalmology. 2009;116:1544–51.
Monnet D, Levinson RD, Holland GN, Haddad L, Yu F, Brézin AP. Longitudinal cohort study of patients with birdshot chorioretinopathy. III. Macular imaging at baseline. Am J Ophthalmol. 2007;144(6):818–28.e2.
Johnson MW. Etiology and treatment of macular edema. Am J Ophthalmol. 2009;147(1):11–21.e1.
Kiss CG, Barisani-Asenbauer T, Maca S, Richter-Mueksch S, Radner W. Reading performance of patients with uveitis-associated cystoid macular edema. Am J Ophthalmol. 2006;142(4):620–4.e1.
Hazel A, Petre K, Armstrong RA. Visual function and subjective quality of life compared in subjects with acquired macular disease. Invest Ophthalmol Vis Sci. 2000;41:1309–15.
Bringmann A, Wiedemann P. Muller glial cells in retinal disease. Ophthalmologica. 2012;227(1):1–19. Epub 17 Sept 2011.
Marmor MF. Mechanisms of fluid accumulation in retinal edema. Doc Ophthalmol. 1999;97:239–49.
Verkman AS, Ruiz-Ederra J, Levin MH. Functions of aquaporins in the eye. Prog Retin Eye Res. 2008;27(4):420–33. Epub 27 May 2008.
Antcliff RJ, Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol. 1999;14:223–32.
Bringmann A, Uckermann O, Pannicke T, Iandiev I, Reichenbach A, Wiedemann P. Neuronal versus glial cell swelling in the ischaemic retina. Acta Ophthalmol Scand. 2005;83(5):528–38. Epub 29 Sept 2005.
Chuang JZ, Chou SY, Sung CH. Chloride intracellular channel 4 is critical for the epithelial morphogenesis of RPE cells and retinal attachment. Mol Biol Cell. 2010;21(17):3017–28. Epub 9 Jul 2010.
Motulsky E, Koch P, Janssens S, Liénart M, Vanbellinghen AM, Bolaky N, et al. Aquaporin expression in blood-retinal barrier cells during experimental autoimmune uveitis. Mol Vis. 2010;16:602–10.
Eberhardt C, Amann B, Feuchtinger A, Hauck SM, Deeg CA. Differential expression of inwardly rectifying K+ channels and aquaporins 4 and 5 in autoimmune uveitis indicates misbalance in Muller glial cell-dependent ion and water homeostasis. Glia. 2011;59(5):697–707. Epub 10 Feb 2011.
van Kooij B, Fijnheer R, Roest M, Rothova A. Trace microalbuminuria in inflammatory cystoid macular edema. Am J Ophthalmol. 2004;138:1010–5.
van Kooij B, Probst K, Fijnheer R, Roest M, de Loos W, Rothova A. Risk factors for cystoid macular oedema in patients with uveitis. Eye. 2008;22(2):256–60.
Forooghian F, Yeh S, Faia LJ, Nussenblatt RB. Uveitis foveal atrophy. Arch Ophthalmol. 2009;127:179–86.
Lin P, Loh AR, Margolis TP, Acharya NR. Cigarette smoking as a risk factor for uveitis. Ophthalmology. 2010;117(3):585–90.
Thorne JE, Daniel E, Jabs DA, Kedhar SR, Peters GB, Dunn JP. Smoking as a risk factor for cystoid macular edema complicating intermediate uveitis. Am J Ophthalmol. 2008;145:841–6.
Kaercher Kramer C, de Azevedo MJ, da Costa Rodrigues T, Canani LH, Esteves J. Smoking habit is associated with diabetic macular edema in type I diabetes mellitus patients. J Diabetes Complications. 2008;22:430.
Glossop JR, Dawes PT, Mattey DL. Association between cigarette smoking and release of tumor necrosis factor α and its soluble receptor by peripheral blood mononuclear cells in patients with rheumatoid arthritis. Rheumatology. 2006;45:1223–9.
Edwards D. Immunological effects of tobacco smoking in “healthy” smokers. COPD. 2009;6(1):48–58. Epub 21 Feb 2009.
Fisher MC, Hochberg MC, El-Taha M, Kremer JM, Peng C, Greenberg JD, et al. Smoking, smoking cessation, and disease activity in large cohort of patients with rheumatoid arthritis. J Rheumatol. 2012;39:904–9.
Costenbader KH, Feskanich D, Mandl LA, Karlson EW. Smoking intensity, duration, and cessation, and risk of rheumatoid arthritis in women. Am J Med. 2006;119:503–11.
Simmons-Rear A, Yeh S, Chan-Kai BT, Lauer AK, Flaxel CJ, Smith JR, et al. Characterization of serous retinal detachments in uveitis patients with optical coherence tomography. J Ophthal Inflamm Infect. 2012;2:191–7.
Sreekantam S, Denniston AK, Murray PI. Survey of expert practice and perceptions of the supporting clinical evidence for the management of uveitis-related cataract and cystoid macular oedema. Ocul Immunol Inflamm. 2011;19(5):353–7. Epub 10 Aug 2011.
Sugar EA, Jabs DA, Altaweel MM, Lightman S, Acharya N, Vitale AT, et al. Identifying a clinically meaningful threshold for change in uveitic macular edema evaluated by optical coherence tomography. Am J Ophthalmol. 2011;152:1044–52.e1045.
Jittpoonkuson T, Garcia P, Rosen RB. Correlation between fluorescein angiography and spectral domain optical coherence tomography in the diagnosis of cystoid macular edema. Br J Ophthalmol. 2010;94:1197–200.
Tran THC, de Smet MD, Bodaghi B, Fardeau C, Cassoux N, Lehoang P. Uveitic macular oedema: correlation between optical coherence tomography patterns with visual acuity and fluorescein angiography. Br J Ophthalmol. 2008;92(7):922–7.
de Smet MD, Okada AA. Cystoid macular edema in uveitis. Dev Ophthalmol. 2010;47:136–47.
Pruett R, Brockhurst RJ, Letts N. Fluorescein angiography of peripheral uveitis. Am J Ophthalmol. 1974;77:448–53.
Pelitli Gürlü V, Alimgil ML, Esgin H. Fluorescein angiographic findings in cases with intermediate uveitis in the inactive phase. Can J Ophthalmol. 2007;42:107–9.
Tugal-Tutkun I, Herbort CP, Kharairallah M, The Angiography Scoring for Uveitis Working Group (ASUWOG). Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis). Int Ophthalmol. 2008;30:539–52.
Gupta V, Gupta P, Singh R, Dogra MR, Gupta A. Spectral-domain Cirrus high-definition optical coherence tomography is better than time-domain stratus optical coherence tomography for evaluation of macular pathologic features in uveitis. Am J Ophthalmol. 2008;145(6):1018–22.e2.
Markomichelakis NN, Halkiadais I, Pantelia E, Peponis V, Patelis A, Theodossiadis P, et al. Patterns of macular edema in patients with uveitis. Qualitative and quantitative assessment using optical coherence tomography. Ophthalmology. 2005;111:946–53.
Roesel M, Henschel A, Heinz C, Spital G, Heiligenhaus A. Time-domain and spectral-domain optical coherence tomography in uveitic macular edema. Am J Ophthalmol. 2008;146(4):626–7.
Ossewaarde-van Norel A, Berg EM, Sijssens KM, Rothova A. Subfoveal serous retinal detachment in patients with uveitis macular edema. Arch Ophthalmol. 2011;129:158–62.
Pilotto E, Vujosevic S, Grgic V, Sportiello P, Convento E, Secchi A, et al. Retinal function in patients with serpiginous choroiditis: a microperimetry study. Graefes Arch Clin Exp Ophthalmol. 2010;248(9):1331–7.
Vujosevic S, Midena E, Pilotto E, Radin PP, Chiesa L, Cavarzeran F. Diabetic macular edema: correlation between microperimetry and optical coherence tomography findings. Invest Ophthalmol Vis Sci. 2006;47(7):3044–51.
Payne JF, Bruce BB, Lee LBK, Yeh S. Logarithmic transformation for spectral-domain optical coherence tomography data in uveitis-associated macular edema. Invest Ophthalmol Vis Sci. 2011;52:8939–43.
Ferris 3rd FL, Miller KM, Glassman AR, Beck RW. A proposed method of logarithmic transformation of optical coherence tomography data for use in clinical research. Ophthalmology. 2010;117(8):1512–6. Epub 7 Apr 2010.
Hajali M, Fishman GA, Anderson RJ. The prevalence of cystoid macular oedema in retinitis pigmentosa patients determined by optical coherence tomography. Br J Ophthalmol. 2008;92(8):1065–8. Epub 26 Jul 2008.
Samuel MA, Equi RA, Chang TS, Mieler WF, Jampol LM, Hay D, et al. Idiopathic retinitis, vasculitis, aneurysms, and neuroretinitis (IRVAN): new observations and a proposed staging system. Ophthalmology. 2007;114:1526–9.
Rothova A. Fuchs’ heterochromic uveitis and Coat’s disease. Ocul Immunol Inflamm. 1994;2:187–8.
Wand M, Shields BM. Cystoid macular edema in the era of ocular hypotensive lipids. Am J Ophthalmol. 2002;133:393–7.
Digiuni M, Fogagnolo P, Rossetti L. A review of the use of latanoprost for glaucoma since its launch. Expert Opin Pharmacother. 2012;13:723–45.
Idris I, Warren G, Donnelly R. Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes. Arch Intern Med. 2012;172(13):1005–11. Epub 13 Jun 2012.
Gelfand JM, Nolan R, Schwartz DM, Graves J, Green AJ. Microcystic macular oedema in multiple sclerosis is associated with disease severity. Brain. 2012;135(Pt 6):1786–93. Epub 28 Apr 2012.
Kloos P, Laube I, Thoelen A. Obstructive sleep apnea in patients with central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2008;246(9):1225–8. Epub 12 Jun 2008.
Mason RH, West SD, Kiire CA, Groves DC, Lipinski HJ, Jaycock A, et al. High prevalence of sleep disordered breathing in patients with diabetic macular edema. Retina. 2012;32(9):1791–8.
Pato E, Munoz-Fernandez S, Francisco F, Abad MA, Maese J, Ortiz A, et al. Systematic review on the effectiveness of immunosuppressants and biological therapies in the treatment of autoimmune posterior uveitis. Semin Arthritis Rheum. 2011;40(4):314–23. Epub 27 Jul 2010.
Ossewaarde-van Norel A, Rothova A. Clinical review: update on treatment of inflammatory macular edema. Ocul Immunol Inflamm. 2011;19(1):75–83. Epub 3 Nov 2010.
Nussenblatt RB, Palestine AG, Chan CC, Stevens G, Mellow SD, Green SB. Randomized, doubled-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol. 1991;112:138–46.
Tehrani NN, Saeed T, Murray PI. Deep intramuscular methylprednisolone for the treatment of cystoid macular oedema in uveitis. Eye. 2000;14:691–4.
Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130(4):492–513.
Leder HA, Jabs DA, Galor A, Dunn JP, Thorne JE. Periocular triamcinolone acetonide injections for cystoid macular edema complicating noninfectious uveitis. Am J Ophthalmol. 2011;152(3):441–8 e2. Epub 10 Jun 2011.
Bae JH, Lee CS, Lee SC. Efficacy and safety of intravitreal bevacizumab compared with intravitreal and posterior sub-tenon triamcinolone acetonide for treatment of uveitis cystoid macular edema. Retina. 2011;31:111–8.
Venkatesh P, Kumar CS, Abbas Z, Garg S. Comparison of the efficacy and safety of different methods of posterior subtenon injection. Ocul Immunol Inflamm. 2008;16(5):217–23.
Choudhry S, Ghosh S. Intravitreal and posterior subtenon triamcinolone acetonide in idiopathic bilateral uveitic macular oedema. Clin Experiment Ophthalmol. 2007;35(8):713–8. Epub 14 Nov 2007.
Habot-Wilner Z, Sallam A, Roufas A, Kabasele PM, Grigg JR, McCluskey P, et al. Periocular corticosteroid injection in the management of uveitis in children. Acta Ophthalmol. 2010;88(8):e299–304. Epub 1 Dec 2010.
Tanner V, Kanski JJ, Frith PA. Posterior sub-Tenon’s triamcinolone injections in the treatment of uveitis. Eye. 1998;12:679–85.
Roesel M, Gutfleisch M, Heinz C, Heimes B, Zurek-Imhoff B, Heiligenhaus A. Intravitreal and orbital floor triamcinolone acetonide injections in noninfectious uveitis: a comparative study. Ophthalmic Res. 2009;42(2):81–6. Epub 30 May 2009.
Roesel M, Gutfleisch M, Heinz C, Heimes B, Zurek-Imhoff B, Heiligenhaus A. Orbital floor triamcinolone acetonide injections for the management of active non-infectious uveitis. Eye (Lond). 2009;23(4):910–4. Epub 10 May 2008.
Cunningham MA, Edelman JL, Kaushal S. Intravitreal steroids for macular edema: the past, the present, and the future. Surv Ophthalmol. 2008;53(2):139–49.
Atmaca L, Yalçindağ F, Özdemir Ö. Intravitreal triamcinolone acetonide in the management of cystoid macular edema in Behçet’s disease. Graefes Arch Clin Exp Ophthalmol. 2007;245(3):451–6.
Park CH, Jaffe GJ, Fekrat S. Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol. 2003;136:419–25.
Martidis A, Duker JS, Puliafito CA. Intravitreal triamcinolone for refractor cystoid macular edema secondary to birdshot retinochoroidopathy. Arch Ophthalmol. 2001;119:1380–3.
Sallam A, Comer RM, Chang JH, Grigg JR, Andrews R, McCluskey PJ, et al. Short-term safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema in children. Arch Ophthalmol. 2008;126(2):200–5.
Choi YJ, Oh IK, Oh JR, Huh K. Intravitreal versus posterior subtenon injection of triamcinolone acetonide for diabetic macular edema. Korean J Ophthalmol. 2006;20:205–9.
Kok H, Lau C, Maycock N, McCluskey P, Lightman S. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology. 2005;112(11):1916.e1-.e7.
Maca SM, Abela-Formanek C, Kiss CG, Sacu SG, Benesch T, Barisani-Asenbauer T. Intravitreal triamcinolone for persistent cystoid macular edema in eyes with quiescent uveitis. Clin Exp Immunol. 2009;37(8):389–96.
Tao Y, Jonas JB. Intravitreal triamcinolone. Ophthalmologica. 2011;225(1):1–20. Epub 10 Aug 2010.
Oueghlani E, Pavesio CE. Intravitreal triamcinolone injection for unresponsive cystoid macular oedema in probable Behçet’s disease as additional therapy. Klin Monatsbl Augenheilkd. 2007;225:497–9.
Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Louis TA, et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology. 2011;118(10):1916–26. Epub 16 Aug 2011.
Pavesio C, Zierhut M, Bairi K, Comstock TL, Usner DW. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology. 2010;117(3):567–75.e1.
Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol. 2008;126(9):1191–201.
Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 2006;113(6):1020–7.
Lowder C, Belfort Jr R, Lightman S, Foster CS, Robinson MR, Schiffman RM, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129(5):545–53. Epub 12 Jan 2011.
Williams GA, Haller JA, Kuppermann BD, Blumenkranz MS, Weinberg DV, Chou C, et al. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine–Gass syndrome. Am J Ophthalmol. 2009;147(6):1048–54.e2.
Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007;125(3):309–17.
Zierhut M, Thiel HJ, Schlote T. Treatment of uveitic macular edema with acetazolamide. Doc Ophthalmol. 1999;97:409–13.
Cox SN, Hay E, Bird AC. Treatment of chronic macular edema with acetazolamide. Arch Ophthalmol. 1988;106:1190–5.
Farber MD, Lam S, Tessler HH, Jennings TJ, Cross A, Rusin MM. Reduction of macular oedema by acetazolamide in patients with chronic iridocyclitis: a randomised prospective crossover study. Br J Ophthalmol. 1994;78:4–7.
Whitcup SM, Csaky KG, Podgor MJ, Chew EY, Perry CH, Nussenblatt RB. A randomized, masked, cross-over trial of acetazolamide for cystoid macular edema in patients with uveitis. Ophthalmology. 1996;103:1054–62.
Lashay AR, Rahimi A, Chams H, Davatchi F, Shahram F, Hatmi ZN, et al. Evaluation of the effect of acetazolamide on cystoid macular oedema in patients with Behcet’s disease. Eye. 2003;17(6):762–6.
Butler NJ, Suhler EB, Rosenbaum JT. Interferon alpha 2b in the treatment of uveitic cystoid macular edema. Ocul Immunol Inflamm. 2012;20(2):86–90. Epub 14 Mar 2012.
Deuter CM, Kotter I, Gunaydin I, Stubiger N, Doycheva DG, Zierhut M. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol. 2009;93(7):906–13. Epub 27 Mar 2009.
Paire V, Lebreton O, Weber M. Effectiveness of interferon alpha in the treatment of uveitis macular edema refractory to corticosteroid and/or immunosuppressive treatment. J Fr Ophtalmol. 2010;33:152–63.
Bodaghi B, Gendron G, Wechsler B, Terrada C, Cassoux N, Thi Huong DL, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol. 2007;91(3):335–9.
Deuter CME, Koetter I, Ouenaydin I, Stuebiger N, Zierhut M. Interferon alfa-2A: a new treatment option for long lasting refractory cystoid macular edema in uveitis? Retina. 2006;26:786–91.
Plskova J, Greiner K, Forrester JV. Interferon-[alpha] as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol. 2007;144(1):55–61.e2.
Kötter I, Eckstein AK, Stübiger N, Zierhut M. Treatment of ocular symptoms of Behçet’s disease with interferon α2a: a pilot study. Br J Ophthalmol. 1998;82:488–94.
Nussenblatt RB, de Smet MD, Rubin B, Freidlin V, Whitcup SM, Davis J, et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. Am J Ophthalmol. 1993;115:583–91.
Whitcup SM, Salvo Jr EC, Nussenblatt RB. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behçet’s disease. Am J Ophthalmol. 1994;118:39–45.
Vitale AT, Rodriguez A, Foster CS. Low-dose cyclosporine therapy in the treatment of birdshot retinochoroidopathy. Ophthalmology. 1994;101:822–31.
Neri P, Mariotti C, Cimino L, Mercanti L, Giovannini A. Long-term control of cystoid macular oedema in noninfectious uveitis with Mycophenolate Mofetil. Int Ophthalmol. 2009;29(3):127–33. Epub 26 Feb 2008.
Doycheva D, Zierhut M, Blumenstock G, Stuebiger N, Deuter C. Mycophenolate mofetil in the therapy of uveitic macular edema – long-term results. Ocul Immunol Inflamm. 2012;20(3):203–11. Epub 12 Apr 2012.
Abu El-Asrar AM, Abboud EB, Aldibhi H, Al-Arfaj A. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behcet’s disease. Int Ophthalmol. 2005;26(3):83–92. Epub 13 Oct 2006.
Cantini F, Niccoli L, Nannini C, Kaloudi O, Cassara E, Susini M, et al. Efficacy of infliximab in refractory Behcet’s disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients. Biologics. 2012;6:5–12. Epub 1 Feb 2012.
Markomichelakis NN, Theodossiadis PG, Pantalia E, Papaefthimiou S, Theodossiadis GP, Sfikakis PP. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol. 2004;138:648–50.
Erckens RJ, Mostard RL, Wijnen PA, Schouten JS, Drent M. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2012;250(5):713–20. Epub 29 Nov 2011.
Farvardin M, Afarid M, Mehryar M, Hosseini H. Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis. Retina. 2010;30:1530–5.
Farvardin M, Afarid M, Shahrzad S. Long-term effects of intravitreal infliximab for treatment of sight-threatening chronic noninfectious uveitis. J Ocul Pharmacol Ther. 2012;28:628–31.
Markomichelakis N, Delicha E, Masselos S, Sfikakis PP. Intravitreal infliximab for sight-threatening relapsing uveitis in Behcet disease: a pilot study in 15 patients. Am J Ophthalmol. 2012;154:534–41.
Androudi S, Tsironi E, Kalogeropoulos C, Theodoridou A, Brazitikos P. Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology. 2010;117(8):1612–6. Epub 10 Apr 2010.
Kafkala C, Choi JY, Choopong P, Foster CS. Octreotide as a treatment for uveitic cystoid macular edema. Arch Ophthalmol. 2006;124:1353–5.
Missotten T, van Laar JAM, van der Loos TL, van Daele PLA, Kuijpers RWAM, Baarsma GS, et al. Octreotide long-acting repeatable for the treatment of chronic macular edema in uveitis. Am J Ophthalmol. 2007;144(6):838–43.
Papadaki T, Zacharopoulos I, Iaccheri B, Fiore T, Foster CS. Somatostatin for uveitic cystoid macular edema (CME). Ocul Immunol Inflamm. 2005;13(6):469–70.
Taylor SR, Habot-Wilner Z, Pacheco P, Lightman S. Intravitreal methotrexate in uveitis. Ophthalmology. 2012;119(4):878–9. Epub 5 Apr 2012.
Taylor SRJ, Habot-Wilner Z, Pacheco P, Lightman SL. Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema. Ophthalmology. 2009;116(4):797–801.
Bae JH, Lee SC. Effect of intravitreal methotrexate and aqueous humor cytokine levels in refractory retinal vasculitis in Behcet disease. Retina. 2012; 32:1395–1402.
Hardwig PW, Pulido JS, Erie JC, Baratz KH, Buettner H. Intraocular methotrexate in ocular diseases other than primary central nervous system lymphoma. Am J Ophthalmol. 2006;142:883–5.
Mirshahi A, Namavari A, Djalilian A, Moharamzad Y, Chams H. Intravitreal bevacizumab (avastin) for the treatment of cystoid macular edema in Behcet disease. Ocul Immunol Inflamm. 2009;17(1):59–64. Epub 19 Mar 2009.
Soheilian M, Rabbanikhah Z, Ramezani A, Kiavash V, Yaseri M, Peyman GA. Intravitreal bevacizumab versus triamcinolone acetonide for refractory uveitic cystoid macular edema: a randomized pilot study. J Ocul Pharmacol Ther. 2010;26(2):199–206. Epub 24 Mar 2010.
Lasave AF, Zeballos DG, El-Haig WM, Diaz-Llopis M, Salom D, Arevalo JF. Short-term results of a single intravitreal bevacizumab (avastin) injection versus a single intravitreal triamcinolone acetonide (kenacort) injection for the management of refractory noninfectious uveitic cystoid macular edema. Ocul Immunol Inflamm. 2009;17(6):423–30. Epub 17 Dec 2009.
Cervantes-Castañeda RA, Giuliari GP, Gallagher MJ, Yilmaz T, MacDonell RE, Quinones K, et al. Intravitreal bevacizumab in refractory uveitic macular edema: one-year follow-up. Eur J Ophthalmol. 2009;19:622–9.
Weiss K, Steinbrugger I, Weger M, Ardjomand N, Maier R, Wegscheider BJ, et al. Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular edema with intravitreal bevacizumab. Eye. 2009;23:1812–8.
Soheilian M, Karimi S, Ramezani A, Peyman GA. Pilot study of intravitreal injection of diclofenac for treatment of macular edema of various etiologies. Retina. 2010;30:509–15.
Kim SJ, Doherty TJ, Cherney EF. Intravitreal ketorolac for chronic uveitis and macular edema. Arch Ophthalmol. 2012;130:456–60.
Pleyer U, Roider J, Heiligenhaus A, Sauer S, Bertram B, Thurau S, et al. Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des berufsverbandes der Augenärzte Deutschlands sur intravitrealen therapie des makual¨dems bei uveitis. Ophthalmologe. 2012;109:93–9.
Acharya NR, Hong KC, Lee SM. Ranibizumab for refractory uveitis-related macular edema. Am J Ophthalmol. 2009;148(2):303–9.e2.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
de Smet, M.D. (2014). Cystoid Macular Edema. In: Pleyer, U., Alió, J., Barisani-Asenbauer, T., Le Hoang, P., Rao, N. (eds) Immune Modulation and Anti-Inflammatory Therapy in Ocular Disorders. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-54350-0_11
Download citation
DOI: https://doi.org/10.1007/978-3-642-54350-0_11
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-54349-4
Online ISBN: 978-3-642-54350-0
eBook Packages: MedicineMedicine (R0)